Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and Bevacizumab in Recurrent Grade 4 Glioma
NCT07541781Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sitagliptin in glioma and glioblastoma (GBM). Primary endpoints: Dose-limiting toxicities at cycle 2 and Change in participants' concentration of circulating MDSCs. Started Jun 2026; status: recruiting.
02
Drugs
sitagliptin
03
Conditions
gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT07541781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541781.